Elisabet Nielsen

Elisabet Nielsen

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Pharmacological Reviews
Verified
Journal Article
Closed access
ENElisabet Nielsen
Elisabet Nielsen
LFLena E. Friberg
Lena E. Friberg
Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an important tool for rational drug development and drug use, where developed models characterize both the typical trends in the data and quantify the variability in relationships between dose, concentration, and desired effects and side effects. In parallel, rapid emergence of antibiotic-resistant bacteria imposes new challenges on modern health care. Models that can characterize bacterial growth, bacterial killing by antibiotics and immune system, and selection of resistance can provide valuable information on the interactions between antibiotics, bacteria, and host. Simulations from developed models allow for outcome predictions of untested scenarios, improved study designs, and optimized dosing regimens. Today, much quantitative information on antibiotic PKPD is thrown away by summarizing data into variables with limited possibilities for extrapolation to different dosing regimens and study populations. In vitro studies allow for flexible study designs and valuable information on time courses of antibiotic drug action. Such experiments have formed the basis for development of a variety of PKPD models that primarily differ in how antibiotic drug exposure induces amplification of resistant bacteria. The models have shown promise for efficacy predictions in patients, but few PKPD models describe time courses of antibiotic drug effects in animals and patients. We promote more extensive use of modeling and simulation to speed up development of new antibiotics and promising antibiotic drug combinations. This review summarizes the value of PKPD modeling and provides an overview of the characteristics of available PKPD models of antibiotics based on in vitro, animal, and patient data.

1 October 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ENElisabet Nielsen
Elisabet Nielsen
OCOtto Cars
Otto Cars
LFLena E. Friberg
Lena E. Friberg
A pharmacokinetic-pharmacodynamic (PKPD) model that characterizes the full time course of in vitro time-kill curve experiments of antibacterial drugs was here evaluated in its capacity to predict the previously determined PK/PD indices. Six drugs (benzylpenicillin, cefuroxime, erythromycin, gentamicin, moxifloxacin, and vancomycin), representing a broad selection of mechanisms of action and PK and PD characteristics, were investigated. For each drug, a dose fractionation study was simulated, using a wide range of total daily doses given as intermittent doses (dosing intervals of 4, 8, 12, or 24 h) or as a constant drug exposure. The time course of the drug concentration (PK model) as well as the bacterial response to drug exposure ( in vitro PKPD model) was predicted. Nonlinear least-squares regression analyses determined the PK/PD index (the maximal unbound drug concentration [ fC max ]/MIC, the area under the unbound drug concentration-time curve [ f AUC]/MIC, or the percentage of a 24-h time period that the unbound drug concentration exceeds the MIC [ fT >MIC ]) that was most predictive of the effect. The in silico predictions based on the in vitro PKPD model identified the previously determined PK/PD indices, with fT >MIC being the best predictor of the effect for β-lactams and f AUC/MIC being the best predictor for the four remaining evaluated drugs. The selection and magnitude of the PK/PD index were, however, shown to be sensitive to differences in PK in subpopulations, uncertainty in MICs, and investigated dosing intervals. In comparison with the use of the PK/PD indices, a model-based approach, where the full time course of effect can be predicted, has a lower sensitivity to study design and allows for PK differences in subpopulations to be considered directly. This study supports the use of PKPD models built from in vitro time-kill curves in the development of optimal dosing regimens for antibacterial drugs.

1 January 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ENElisabet Nielsen
Elisabet Nielsen
AVAnders Viberg
Anders Viberg
ELElisabeth LöwDin
Elisabeth LöwDin
OCOtto Cars
Otto Cars
MKMats O. Karlsson
Mats O. Karlsson
MSMarie Sandström
Marie Sandström
Dosing of antibacterial agents is generally based on point estimates of the effect, even though bacteria exposed to antibiotics show complex kinetic behaviors. The use of the whole time course of the observed effects would be more advantageous. The aim of the present study was to develop a semimechanistic pharmacokinetic (PK)/pharmacodynamic (PD) model characterizing the events seen in a bacterial system when it is exposed to antibacterial agents with different mechanisms of action. Time-kill curve experiments were performed with a strain of Streptococcus pyogenes exposed to a wide range of concentrations of the following antibiotics: benzylpenicillin, cefuroxime, erythromycin, moxifloxacin, and vancomycin. Bacterial counts were monitored with frequent sampling during the experiment. A simultaneous fit of all data was accomplished. The degradation of the drugs was monitored and corrected for in the model, and a link model was used to account for an effect delay. In the final PK/PD model, the total bacterial population was divided into two subpopulations: one growing drug-susceptible population and one resting insusceptible population. The drug effect was included as an increase of the killing rate of bacteria in the susceptible state, according to a maximum-effect ( E max ) model. An internal model validation showed that the model was robust and had good predictability. In conclusion, for all drugs, the final PK/PD model successfully described bacterial growth and killing kinetics when the bacteria were exposed to different antibiotic concentrations. The semimechanistic model that was developed might, after further refinement, serve as a tool for the development of optimal dosing strategies for antibacterial agents.

13 December 2021 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
JBJurgen Brem
Jurgen Brem
TPTharindi Panduwawala
Tharindi Panduwawala
JHJon Ulf Hansen
Jon Ulf Hansen
JHJoanne Hewitt
Joanne Hewitt
ELEdgars Liepins
Edgars Liepins
CSChristopher J. Schofield
Christopher J. Schofield

1 June 2009 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ENElisabet Nielsen
Elisabet Nielsen
MSMarie Sandström
Marie Sandström
PHPer Hartvig Honoré
Per Hartvig Honoré
UEUwe Ewald
Uwe Ewald
LFLena E. Friberg
Lena E. Friberg

14 February 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JAJoão A. Abrantes
João A. Abrantes
SJSiv Jonsson
Siv Jonsson
MKMats O. Karlsson
Mats O. Karlsson
ENElisabet Nielsen
Elisabet Nielsen
Aims: This study aims to assess approaches to handle interoccasion variability (IOV) in a model‐based therapeutic drug monitoring (TDM) context, using a population pharmacokinetic model of coagulation factor VIII as example.Methods: We assessed 5 model‐based TDM approaches: empirical Bayes estimates (EBEs) from a model including IOV, with individualized doses calculated based on individual parameters either (i) including or (ii) excluding variability related to IOV; and EBEs from a model excluding IOV by (iii) setting IOV to zero, (iv) summing variances of interindividual variability (IIV) and IOV into a single IIV term, or (v) re‐estimating the model without IOV. The impact of varying IOV magnitudes (0–50%) and number of occasions/observations was explored. The approaches were compared with conventional weight‐based dosing. Predictive performance was assessed with the prediction error percentiles.Results: When IOV was lower than IIV, the accuracy was good for all approaches (50th percentile of the prediction error [P50] <7.4%), but the precision varied substantially between IOV magnitudes (P97.5 61–528%). Approach (ii) was the most precise forecasting method across a wide range of scenarios, particularly in case of sparse sampling or high magnitudes of IOV. Weight‐based dosing led to less precise predictions than the model‐based TDM approaches in most scenarios.Conclusions: Based on the studied scenarios and theoretical expectations, the best approach to handle IOV in model‐based dose individualization is to include IOV in the generation of the EBEs but exclude the portion of unexplained variability related to IOV in the individual parameters used to calculate the future dose.